Join Here   |   Log In

Inflammation as a Cause of Depression and Anxiety

Key takeaways:

  • Chronically elevated inflammation causes depression and anxiety, for some people…
  • Genetics may help point to whether this is an underlying cause for you.
  • Finding your underlying physiological cause of depression or anxiety may lead you to the solutions that are right for you.

This article explains why inflammation causes depression and how your genetic variants in inflammatory genes may play a role in depression or anxiety. Members will see their genotype report below, plus additional solutions in the Lifehacks section. Join today

Depression and Anxiety: Inflammation as a root cause

Research over the past two decades clearly shows a causal link between increased inflammatory markers and depression. This means that inflammation – elevated levels of inflammatory cytokines – can CAUSE mood disorders, for at least a portion of depressed patients. Addressing inflammation as an underlying factor helps to resolve depression or anxiety for many, but not all. And your genes may hold the key here.[ref][ref]

There’s currently a push in psychiatry to include in the DSM a specific subtype of depression linked to inflammation.[ref] Inflammation-driven depression is characterized by:[ref]

  • sleep problems
  • tiredness, lack of energy
  • changes in appetite
  • anhedonia (meh, feeling like nothing matters)

Genetic studies show causality:
One way to determine if inflammation is a root cause of mood disorders is to look at the genetic variants that increase susceptibility to depression or anxiety. In this case, research shows that a bunch of genetic risk factors for mood disorders are in inflammation-related genes.[ref][ref] Deleting certain inflammation genes causes animals to be resistant to stress-induced depression.[ref]

Animal models of depression let researchers experiment to determine causality. Increasing inflammatory cytokines clearly causes depression and anxiety symptoms in animals, and decreasing the inflammation takes away the symptoms.[ref] Additionally, human studies show that drugs that decrease inflammation significantly improve depression in some people.[ref]

Disclaimer: This article is a presentation of the research on depression, anxiety, and inflammation. It is not to be taken as medical advice. If you are under the care of a physician for a mood disorder, please talk with your provider for medical advice.

Inflammatory cytokines cause behavior changes:

Behavior changes when you get sick. You’re tired, irritable, and don’t want to interact with people. If you have kids, you learn to spot these signs they’re fighting off ‘a bug’ very quickly. Even in pets, you will see that they withdraw, sleep, and avoid others when they are sick. Appetite changes, and they often are hyper-vigilant as well.

Researchers call this ‘sickness behavior‘, and it’s apparent across all species of animals. It’s instinctive. The best way not to infect your family (or herd, pack, tribe, flock, group) is to curl up in a corner and avoid everyone.

What drives this response? Researchers in the 1980s made a key discovery. Interferon-alpha, an inflammatory cytokine that fights viruses, was first used in the 80s as a treatment for chronic hepatitis. Some patients reacted immediately to the interferon-alpha with psychiatric side effects, including depression, emotional instability, paranoia, agitation, and suicidal potential. These side effects occurred in patients on the highest doses of interferon-alpha, and reducing the dose took away the psychiatric problems.[ref][ref][ref]

5 common causes of inflammation in depression and anxiety:

While this is a huge topic, here are five of the factors that explain why depression and anxiety are so prevalent today.

#1 Gut dysbiosis and increased permeability:
Your intestinal barrier keeps the microbes in your gut separate from the rest of your body. Lining your intestines is a mucosal barrier that keeps the gut microbes away from the epithelial cells, which keep out microbes by being tightly joined together. Reducing the mucosal lining and/or loosening the tight junctions in your intestinal barrier can increase your inflammatory response to your gut bacteria. A study on patients with major depressive disorder showed that patients have higher than average activity of the inflammatory markers for dealing with bacteria from the gut.[ref]

PMC7915869, CC

What can cause gut dysbiosis and increased intestinal permeability? A diet that includes a lot of junk food. (read about emulsifiers, food additives, and inflammation)

#2 Autoimmune diseases and allergies:
Many autoimmune diseases, including lupus, multiple sclerosis, psoriasis, and rheumatoid arthritis, have links to an increase in inflammation. People with these autoimmune issues are also at an increased risk of depression. Allergies and asthma also have links to an increased risk of depression. For example, a meta-analysis calculated that the prevalence of depression in people with rheumatoid arthritis is ~39%.[ref][ref][ref][ref][ref][ref]

#3 Stress:
The body undergoes a series of physical changes when stressed. Major life events, such as losing a job, the death of a loved one, moving, or divorce, cause stress in the body. The stress response initiates pro-inflammatory cytokine production to enhance wound healing and improve physical recovery. In fact, to create an animal model of anxiety or depression, researchers simply subject animals to mild, unpredictable stress (tilting the cage, intermittent light, noise).[ref]

#4 Omega 6: Omega 3 ratio:
Consuming a higher ratio of omega-6 to omega-3 fats increases inflammation. Omega-6 fats are found in oils such as soybean, corn, vegetable oil, sunflower, and other seed oils, which are all prevalent in a modern diet. An excess of omega-6 oils causes an increase in overall inflammation.[ref]

A 2026 placebo-controlled clinical trial showed that supplementing with DHA and EPA, omega-3 fatty acids, significantly reduced depression, stress, and anxiety symptoms (compared to a placebo group taking corn oil).[ref]

Why would DHA and EPA help?  The resolution of inflammation is an active process that involves specific lipid mediators. The omega-3 fatty acids DHA and EPA are the biological starting points for the cells to create lipid mediators that resolve inflammation.[ref]

Related article: Resolution of inflammation and specialized pro-resolving mediators

#5 Obesity:
Higher overall inflammation goes hand-in-hand with weight gain. Adipose tissue (fat) gives off inflammatory cytokines, increasing the overall burden of inflammation. People who are overweight and have depression also have higher inflammatory markers, on average, than normal-weight people with depression.[ref][ref]

Why does inflammation affect the brain and mood?

There are a couple of ways that inflammation directly affects the brain:

Increased inflammatory cytokines throughout the body will directly increase the permeability of the blood-brain barrier. This allows the inflammatory cytokines to enter the brain, triggering functional changes in certain brain regions.

  • Higher levels of TNF-alpha in the hippocampus and striatum (brain regions) have links to anxiety and depression in animal studies. TNF-alpha directly causes the release of glutamate in the hippocampus, causing depressive behavior in animals. (Read about TNF genes)
  • IL-1β decreases neurogenesis via the kynurenine pathway.[ref] (read about kynurenine genes)
  • Inflammation decreases the synthesis of neurotransmitters through the disruption of BH4, which is needed for dopamine and serotonin synthesis.[ref] (Read about BH4 genes)
  • TNF-alpha and IL-1 increase the reuptake of serotonin, leaving less serotonin available.[ref] (read about serotonin genes)
  • Increased inflammation shifts the body from converting tryptophan into serotonin and instead produces kynurenine, which has a neurotoxic metabolite called quinolinic acid.[ref] We’ll come back to this in more detail below.

Which inflammatory cytokines are linked to depression or anxiety?

Depression: Research shows that some people with depression have higher levels of TNFα, IL-6, IL-13, IL-18, IL-12, and IL-1RA.[ref] The “IL” stands for interleukin, which is a whole family of inflammatory molecules.

Anxiety: Studies also show that TNF-alpha, IL-6, and C-reactive protein (CRP) have links to anxiety disorders in some people.[ref]

PTSD: Studies on PTSD, which is grouped with anxiety disorders, show that trauma elevates IL-1B, IL-6, TNF-alpha, and C-reactive protein. Generalized anxiety disorder (GAD) has links to increased levels of TNF-alpha and CRP.[ref]

Brain imaging studies point to higher levels of CRP (C-reactive protein), which is a general marker of inflammation and is predictive of psychosis. Additionally, increasing IL-10, which is anti-inflammatory, is linked with greater symptom improvement in depression.[ref]

Scientists have also narrowed down that stress-induced depression is more likely to have pro-inflammatory cytokines as a cause.[ref]

Details on TNF-alpha

TNF-alpha (tumor necrosis factor alpha) is one of the body’s primary inflammatory cytokines. Its production occurs by activated immune cells, such as macrophages, mast cells, B cells, and lymphocytes. It can also be produced in other cells, such as smooth muscle cells, in response to an injury. Adipose tissue (fat tissue) also secretes TNF-alpha.[ref][ref]

When TNF-alpha is elevated in depressed people, blocking TNF-alpha can ameliorate depressive symptoms. A 2008 genome-wide association study found that a TNF genetic variant increases the risk of depression.[ref]

People with rheumatoid arthritis are often given drugs to decrease TNF-alpha. The anti-TNF drugs decrease the frequency of anxiety disorders and depression in people with RA.[ref]

Researchers think that inflammation, specifically high TNF-alpha levels, impacts the HPA axis and elevates cortisol as well. HPA axis dysfunction is strongly linked to depression.

Related article: HPA axis dysfunction: genes and environment

Additionally, higher TNF-alpha levels can cause increased uptake of serotonin into cells, causing depressive symptoms.[ref]

The phrase ‘it’s all in your head’ could be literally true for some people with TNF-alpha variants. A brain-imaging study found that a TNF-alpha genetic variant associated with higher TNF levels was linked to anatomical brain changes in people with major depressive disorder.[ref]

Elevated Interleukin-6

Encoded by the IL6 gene, interleukin-6 (IL-6) is another inflammatory cytokine shown to be consistently elevated in depression.

Animal studies show that inducing an elevated level of IL-6 causes depressive behavior. This can be done using stressful situations or by injecting lipopolysaccharide, an endotoxin from bacteria.[ref] Animals bred not to produce IL-6 are resistant to despair behavior usually induced by stress.[ref]

Genetic studies in humans also link higher levels of IL-6, stressful life events, and an increased risk of depression.[ref]

Interleukin-6 is one of the major cytokines released by immune cells in response to a pathogen or toxin. Chronic or acute stress can also cause the release of IL-6. In the brain, increased levels of IL-6 cause decreased neurotransmitters, including serotonin. Additionally, IL-6 causes a decrease in brain-derived neurotrophic factor (BDNF) and impacts the HPA axis. All of these pathways are implicated in mood disorders.[ref]

PMC7139933, CC

IL-6 also impacts the amygdala’s response to socially threatening situations linking the increased immune response to greater social disconnect, fatigue, and cognitive disturbance.[ref]

Kynurenine pathway:

Tryptophan is an essential amino acid found in many foods that contain protein.

In the body, tryptophan can go down two different pathways:

  • tryptophan can be used to make serotonin and melatonin
  • tryptophan can convert into kynurenine and then into several other metabolites, including quinolinic acid.

Kynurenine can form quinolinic acid, which is a neurotoxin. This is part of the pathway, though, that eventually produces niacin (vitamin B3).

Tryptophan metabolism needs to balance out. The body and brain need serotonin as an important neurotransmitter. Melatonin, produced from serotonin, is an integral part of the circadian system as well as a vital anti-inflammatory molecule.

Increased inflammation causes a shift from tryptophan being used for serotonin to being used for the kynurenine pathway. This causes a double whammy – lower serotonin and higher quinolinic acid. Quinolinic acid acts on NMDA receptors, and too much can kill off brain cells. Studies show that depression scores correlate to higher quinolinic acid in the blood, and postmortem studies show more cells in the brain producing quinolinic acid in suicide victims.[ref]

Hepatitis C patients treated with interferon-alpha have depression and higher kynurenine metabolites.[ref]

Another reason tryptophan metabolism could tilt more towards kynurenine is when the body is lacking in niacin. Providing enough niacin through the diet is important here.

Genetic variants in the IDO1 gene also can skew the body towards producing kynurenine instead of serotonin. (Read more about tryptophan, kynurenine, serotonin, and genetics.)

 

Allergies, COVID-19, and depression and anxiety:

A study of the psychological impact of COVID-19 revealed that people with allergies, which chronically raise inflammatory cytokine levels, were more likely to have PTSD and depression after COVID-19.[ref]

Another study found that people with systemically elevated inflammation after COVID-19 illness were at an increased risk of depression, anxiety, or PTSD.[ref]

While there is a lot of swirl and science about long-haul COVID symptoms, previous research on other viruses that remain active or reactivate (e.g., Epstein-Barr virus, cytomegalovirus) also has links between infection, inflammatory cytokines, and depression.[ref]


Inflammation, Depression, and Anxiety: Genotype Report

Access this content:

An active subscription is required to access this content.

Join as a member


 


Lifehacks:

Talk with your healthcare provider about any supplements or changes – especially if you are on medications.

The lifehacks below deal with ways to suppress inflammatory cytokines, but the obvious solution is to take away the source of the inflammation. Thus, these lifehacks may help in the immediate timeframe, but for a long-term solution, you need to figure out the source of your inflammation (e.g., obesity, stress, diet, gut dysbiosis).

You may find that multiple solutions stacked together work best. For example, curcumin + exercise + an anti-inflammatory diet may be more effective than just popping a curcumin supplement.

Anti-inflammatory OTC medications:

  • Aspirin: Aspirin is a COX-1 and COX-2 inhibitor, which reduces TNF-alpha, IL-6, and CRP. Human studies on aspirin for depression have been small and inconclusive, but research does show that aspirin, along with an SSRI, shortened the time it took for the antidepressant to work.[ref]
  • NSAIDs: Naproxen and ibuprofen reduced depression scores in people who also had osteoarthritis.[ref] Studies on NSAIDs in people without an inflammatory condition show no results for depression.

Who might this work best for? Individuals with genetic variants in TNF, IL6, IL6R

Access this content:

An active subscription is required to access this content.

Join as a member



Related Articles and Topics:

Circadian rhythm disruption as a root cause of depression

Tryptophan Pathways: Kynurenine, Serotonin, and Melatonin

Lithium Orotate and Vitamin B12: Benefits for Mood and Cognitive Support

 


References:

Jha, Manish K., et al. “Should Inflammation Be a Specifier for Major Depression in the DSM-6?” JAMA Psychiatry, vol. 82, no. 6, June 2025, pp. 549–50. PubMed, https://doi.org/10.1001/jamapsychiatry.2025.0206.

Adzic, Miroslav, et al. “Therapeutic Strategies for Treatment of Inflammation-Related Depression.” Current Neuropharmacology, vol. 16, no. 2, Feb. 2018, pp. 176–209. PubMed Central, https://doi.org/10.2174/1570159X15666170828163048.
Azhar, Wedad, et al. “The Effects of Omega-3 Supplementation on Stress, Anxiety, Depression, Sleep Quality, and Everyday Memory in Individuals with Psychological Distress: A Randomized, Double-Blind, Placebo-Controlled Trial.” Journal of Affective Disorders, vol. 399, Apr. 2026, p. 121055. ScienceDirect, https://doi.org/10.1016/j.jad.2025.121055.
Barnes, Jacob, et al. “Genetic Contributions of Inflammation to Depression.” Neuropsychopharmacology, vol. 42, no. 1, Jan. 2017, pp. 81–98. PubMed Central, https://doi.org/10.1038/npp.2016.169.
Bennett, Jeanette M., et al. “Inflammation and Reactivation of Latent Herpesviruses in Older Adults.” Brain, Behavior, and Immunity, vol. 26, no. 5, July 2012, pp. 739–46. PubMed Central, https://doi.org/10.1016/j.bbi.2011.11.007
Bruno, Antonio, et al. “Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis.” Frontiers in Cellular Neuroscience, vol. 14, June 2020, p. 169. PubMed Central, https://doi.org/10.3389/fncel.2020.00169.
Carandini, Tiziana, et al. “The Distinct Roles of Monoamines in Multiple Sclerosis: A Bridge between the Immune and Nervous Systems?” Brain, Behavior, and Immunity, vol. 94, May 2021, pp. 381–91. PubMed, https://doi.org/10.1016/j.bbi.2021.02.030.
Chourbaji, Sabine, et al. “IL-6 Knockout Mice Exhibit Resistance to Stress-Induced Development of Depression-like Behaviors.” Neurobiology of Disease, vol. 23, no. 3, Sept. 2006, pp. 587–94. PubMed, https://doi.org/10.1016/j.nbd.2006.05.001.
Dowlati, Yekta, et al. “A Meta-Analysis of Cytokines in Major Depression.” Biological Psychiatry, vol. 67, no. 5, Mar. 2010, pp. 446–57. PubMed, https://doi.org/10.1016/j.biopsych.2009.09.033.
Du, Yi-Jie, et al. “Airway Inflammation and Hypothalamic-Pituitary-Adrenal Axis Activity in Asthmatic Adults with Depression.” The Journal of Asthma: Official Journal of the Association for the Care of Asthma, vol. 50, no. 3, Apr. 2013, pp. 274–81. PubMed, https://doi.org/10.3109/02770903.2013.765891.
Fredman, Gabrielle, and Katherine C MacNamara. “Atherosclerosis Is a Major Human Killer and Non-Resolving Inflammation Is a Prime Suspect.” Cardiovascular Research, vol. 117, no. 13, Oct. 2021, pp. 2563–74. PubMed Central, https://doi.org/10.1093/cvr/cvab309.
Gonzalez-Diaz, Sandra Nora, et al. “Psychological Impact of the COVID-19 Pandemic on Patients with Allergic Diseases.” The World Allergy Organization Journal, vol. 14, no. 3, Mar. 2021, p. 100510. PubMed, https://doi.org/10.1016/j.waojou.2021.100510.
Huet, Lison, et al. “Relationship between Body Mass Index and Neuropsychiatric Symptoms: Evidence and Inflammatory Correlates.” Brain, Behavior, and Immunity, vol. 94, May 2021, pp. 104–10. PubMed, https://doi.org/10.1016/j.bbi.2021.02.031.
Iyengar, Rupa L., et al. “NSAIDs Are Associated with Lower Depression Scores in Patients with Osteoarthritis.” The American Journal of Medicine, vol. 126, no. 11, Nov. 2013, p. 1017.e11-18. PubMed, https://doi.org/10.1016/j.amjmed.2013.02.037.
Kalyoncu, O. Ayhan, et al. “Major Depressive Disorder with Psychotic Features Induced by Interferon-Alpha Treatment for Hepatitis C in a Polydrug Abuser.” Journal of Psychopharmacology (Oxford, England), vol. 19, no. 1, Jan. 2005, pp. 102–05. PubMed, https://doi.org/10.1177/0269881105048905.
Köhler, C. A., et al. “Peripheral Cytokine and Chemokine Alterations in Depression: A Meta-Analysis of 82 Studies.” Acta Psychiatrica Scandinavica, vol. 135, no. 5, May 2017, pp. 373–87. PubMed, https://doi.org/10.1111/acps.12698.
Kose, Melisa, et al. “The Role of Peripheral Inflammation in Clinical Outcome and Brain Imaging Abnormalities in Psychosis: A Systematic Review.” Frontiers in Psychiatry, vol. 12, 2021, p. 612471. PubMed, https://doi.org/10.3389/fpsyt.2021.612471.
Laguno, Montserrat, et al. “Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C.” Antiviral Therapy, vol. 9, no. 6, Dec. 2004, pp. 905–09. PubMed.
Lee, Chieh-Hsin, and Fabrizio Giuliani. “The Role of Inflammation in Depression and Fatigue.” Frontiers in Immunology, vol. 10, July 2019, p. 1696. PubMed Central, https://doi.org/10.3389/fimmu.2019.01696.
Ma, Ke, et al. “Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review.” International Journal of Molecular Sciences, vol. 17, no. 5, May 2016, p. 733. PubMed Central, https://doi.org/10.3390/ijms17050733.
Marrie, Ruth Ann, et al. “Increased Incidence of Psychiatric Disorders in Immune-Mediated Inflammatory Disease.” Journal of Psychosomatic Research, vol. 101, Oct. 2017, pp. 17–23. PubMed, https://doi.org/10.1016/j.jpsychores.2017.07.015.
Matcham, Faith, et al. “The Prevalence of Depression in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.” Rheumatology (Oxford, England), vol. 52, no. 12, Dec. 2013, pp. 2136–48. PubMed, https://doi.org/10.1093/rheumatology/ket169.
Mazza, Mario Gennaro, et al. “Persistent Psychopathology and Neurocognitive Impairment in COVID-19 Survivors: Effect of Inflammatory Biomarkers at Three-Month Follow-Up.” Brain, Behavior, and Immunity, vol. 94, May 2021, pp. 138–47. PubMed, https://doi.org/10.1016/j.bbi.2021.02.021.
McLaughlin, Anna P., et al. “The Influence of Comorbid Depression and Overweight Status on Peripheral Inflammation and Cortisol Levels.” Psychological Medicine, vol. 52, no. 14, Oct. 2022, pp. 3289–96. PubMed, https://doi.org/10.1017/S0033291721000088.
Michopoulos, Vasiliki, et al. “Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond.” Neuropsychopharmacology, vol. 42, no. 1, Jan. 2017, pp. 254–70. PubMed Central, https://doi.org/10.1038/npp.2016.146.
Miller, Andrew H., et al. “Cytokine Targets in the Brain: Impact on Neurotransmitters and Neurocircuits.” Depression and Anxiety, vol. 30, no. 4, Apr. 2013, pp. 297–306. PubMed Central, https://doi.org/10.1002/da.22084.
Pawlowski, Tomasz, et al. “The Role of Anthranilic Acid in the Increase of Depressive Symptoms and Major Depressive Disorder during Treatment for Hepatitis C with Pegylated Interferon-Α2a and Oral Ribavirin.” Journal of Psychiatry & Neuroscience: JPN, vol. 46, no. 1, Jan. 2021, pp. E166–75. PubMed, https://doi.org/10.1503/jpn.190139.
Pitsavos, Christos, et al. “Anxiety in Relation to Inflammation and Coagulation Markers, among Healthy Adults: The ATTICA Study.” Atherosclerosis, vol. 185, no. 2, Apr. 2006, pp. 320–26. ScienceDirect, https://doi.org/10.1016/j.atherosclerosis.2005.06.001.
Renault, P. F., et al. “Psychiatric Complications of Long-Term Interferon Alfa Therapy.” Archives of Internal Medicine, vol. 147, no. 9, Sept. 1987, pp. 1577–80. PubMed.
Sanna, Livia, et al. “Atopic Disorders and Depression: Findings from a Large, Population-Based Study.” Journal of Affective Disorders, vol. 155, Feb. 2014, pp. 261–65. PubMed, https://doi.org/10.1016/j.jad.2013.11.009.
Slavich, George M., and Michael R. Irwin. “From Stress to Inflammation and Major Depressive Disorder: A Social Signal Transduction Theory of Depression.” Psychological Bulletin, vol. 140, no. 3, May 2014, pp. 774–815. PubMed Central, https://doi.org/10.1037/a0035302.
Suneson, Klara, et al. “Inflammatory Depression—Mechanisms and Non-Pharmacological Interventions.” International Journal of Molecular Sciences, vol. 22, no. 4, Feb. 2021, p. 1640. PubMed Central, https://doi.org/10.3390/ijms22041640.
Ting, Emily Yi-Chih, et al. “Role of Interleukin-6 in Depressive Disorder.” International Journal of Molecular Sciences, vol. 21, no. 6, Mar. 2020, p. 2194. PubMed Central, https://doi.org/10.3390/ijms21062194.
Tzanavari, T., et al. “TNF-Alpha and Obesity.” Current Directions in Autoimmunity, vol. 11, 2010, pp. 145–56. PubMed, https://doi.org/10.1159/000289203.
Uguz, Faruk, et al. “Anti‐tumor Necrosis Factor‐α Therapy Is Associated with Less Frequent Mood and Anxiety Disorders in Patients with Rheumatoid Arthritis.” Psychiatry and Clinical Neurosciences, vol. 63, no. 1, Feb. 2009, pp. 50–55. DOI.org (Crossref), https://doi.org/10.1111/j.1440-1819.2008.01905.x.
Verdonk, Franck, et al. “Microglial Production of Quinolinic Acid as a Target and a Biomarker of the Antidepressant Effect of Ketamine.” Brain, Behavior, and Immunity, vol. 81, Oct. 2019, pp. 361–73. ScienceDirect, https://doi.org/10.1016/j.bbi.2019.06.033.
Zhou, Rubai, et al. “Effects of Tumor Necrosis Factor-α Polymorphism on the Brain Structural Changes of the Patients with Major Depressive Disorder.” Translational Psychiatry, vol. 8, Oct. 2018, p. 217. PubMed Central, https://doi.org/10.1038/s41398-018-0256-x.

About the Author:
Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.